Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Notes Payables (2016)

Eledon Pharmaceuticals filings provide 1 years of Notes Payables readings, the most recent being $3.4 million for Q4 2016.

  • On a quarterly basis, Notes Payables changed N/A to $3.4 million in Q4 2016 year-over-year; TTM through Dec 2016 was $3.4 million, a N/A change, with the full-year FY2016 number at $3.4 million, changed N/A from a year prior.
  • Notes Payables hit $3.4 million in Q4 2016 for Eledon Pharmaceuticals.
  • In the past five years, Notes Payables ranged from a high of $3.4 million in Q4 2016 to a low of $3.4 million in Q4 2016.